Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study tests if exercise can save your muscles while on Weight-Loss drugs

NCT ID NCT07554417

Disease control Sponsor: William Marsh Rice University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a 12-week program of exercise and personalized diet counseling can help preserve muscle mass in obese adults taking GLP-1 medications like Wegovy. Twenty participants aged 40-55 will be followed to see if these lifestyle changes prevent the muscle loss often seen with rapid weight loss. The goal is to make GLP-1 treatment safer and more effective.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Semaglutide (Wegovy), plus dietary counseling and exercise
What this could lead to
If it works, this could show that adding exercise and diet counseling to GLP-1 treatment helps preserve muscle mass while losing weight, leading to safer weight management.
What could go wrong
This is a very small early-phase trial with only 20 participants, so results may not apply to everyone. The exercise program is supervised and may be hard to maintain long-term.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 20 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Apr 2026

An estimate. Start dates often move.

Expected to finish

Aug 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 to 55 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age between 40 and 55 years * Body Mass Index (BMI) greater than 30 * Body fat percentage greater than 30% for males and 40% for females * Android to gynoid fat ratio greater than 1.0 * Currently eligible for GLP-1 therapy * No diagnosis of Type II diabetes Exclusion Criteria: * Presence of abnormal ECG findings, including arrhythmias or ischemic changes * Hypertensive response to exercise, defined as systolic blood pressure exceeding 250 mmHg or diastolic pressure exceeding 115 mmHg * Hypotensive response to exercise, defined as a drop in systolic pressure greater than 10 mmHg with increasing workload * VO₂ max below 15 ml/kg/min * Borg Rating of Perceived Exertion (RPE) greater than 19 during submaximal workloads * Any contraindications to exercise as defined by ACSM guidelines * Musculoskeletal limitations that prevent safe participation in exercise

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Dietary assessment are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

muscular atrophy Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Dietary assessment Exercise intervention GLP-1 Muscle loss Obesity & overweight

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Rice University

    Houston, Texas, 77005, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.